Using amantadine to help stroke recovery
Official title: Promoting Recovery After STroke With Amantadine
Run by University of Pennsylvania · NCT05140148 · Data updated 2026-11-12
This study tests if the medication amantadine can help people recover better after having a stroke.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | University of Pennsylvania Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Status | Recruiting |
| Started | February 1, 2022 |
| Main results expected | December 31, 2027 |
| Study ends | June 30, 2028 |
| Registry record updated | March 30, 2026 |
| Trial ID | NCT05140148 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 to 85 who have experienced an ischemic or hemorrhagic stroke and meet specific neurological assessment criteria.
✕Probably not a fit
Patients with significant expressive or receptive aphasia, or those with primary subarachnoid hemorrhage, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effectiveness of amantadine in promoting recovery in patients who have experienced ischemic or hemorrhagic strokes. Participants will be randomly assigned to receive either amantadine or a placebo for one month, with a total enrollment period of three months. Throughout the trial, patients will undergo assessments and complete questionnaires to evaluate their recovery progress. The study aims to provide insights into the potential benefits of amantadine for stroke rehabilitation.
Why it matters
Potential benefit: If successful, this study could enhance recovery outcomes for stroke patients, potentially improving their quality of life.
How similar studies have gone: Previous studies have explored the use of amantadine for stroke recovery, showing promising results, but this specific approach is still being evaluated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 18 to 85 years old, male and female 2. Modified Rankin Score (mRS)\<=2 prior to stroke 3. Ischemic or hemorrhagic stroke as diagnosed by vascular neurologist or as proven on magnetic resonance imaging (MRI) or non-contrast head computed tomography NCHCT) 4. 24 hours to 3 weeks after stroke onset or time last known well prior to detection of symptoms 5. National Institute of Health Stroke Scale (NIHSS)\>=3 and NIHSS\<=15 6. Creatinine Clearance of greater than or equal to 60 mL/min using the Cockroft- Gault equation. 7. Have passed a swallow evaluation prior to drug administration 8. The patient is an acute rehabilitation candidate or candidate for the Homeward Stroke Program 9. Able to participate in administered tests Exclusion Criteria: 1. Any degree of receptive aphasia 2. Moderate or severe expressive aphasia 3. Currently pregnant or plans to get pregnant 4. Currently breastfeeding 5. Any patient admitted with primary SubarachnoidH emorrhage (SAH )on either non-contrast head CT or MRI brain 6. Diagnosis of dementia or mild cognitive impairment prior to index stroke 7. Prior limb amputation 8. Currently prescribed or taking a primary anticholinergic medication 9. Currently enrolled in any other investigational pharmacologic or procedural clinical trial 10. Malignancy with active treatment 11. History of prior stroke with residual impairment 12. Current or prior neuroleptic use 13. History of suicidality or psychosis (The Columbia Suicide Severity Ratings Scale (C-SSRS) will be administered at the screening visit to assess depression and suicidal thoughts for subject eligibility. Any subjects who indicate severe depression or suicidal thoughts and/or attempts within the last year will not be eligible) 14. Prior history of seizures 15. Prior treatment with amantadine 16. Parkinson's disease 17. Amantadine allergy 18. Elevated liver function tests (aspartate aminotransferase and alanine aminotransferase above the upper limit of normal) -
Where it's running
-
The Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Study coordinator: Aaron Rothstein, M.D
- Email: aaron.rothstein@pennmedicine.upenn.edu
- Phone: 267-624-4442
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Emergency Stroke Unit for treating acute strokes
This study is testing a new Emergency Stroke Unit that uses a mobile MRI to see if it can help treat stroke patients faster and improve their recovery.
-
Comparing reactive balance training with and without electrical stimulation for stroke recovery
This study is testing whether adding electrical stimulation to balance training can help people who have had a stroke improve their balance better than training without it.
-
Using the Atalante exoskeleton to help stroke patients walk again
This study is testing if using the Atalante exoskeleton can help stroke patients walk better compared to regular therapy.
-
Understanding how vision loss affects driving in virtual reality
This study tests how vision loss from a stroke affects driving skills in a virtual reality setting to help understand the challenges faced by people with visual field defects.
-
Evaluating C7 Nerve Transfer for Stroke Recovery
This study is testing if a surgery that connects a healthy part of the brain to the arm can help people who haven't improved their arm function after a stroke for 1-5 years.
-
Early rehabilitation using EEG neurofeedback for stroke recovery
This study tests if using brainwave feedback along with regular rehab can help stroke patients recover better use of their arms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.